Driving Progress in Rare Liver Disease: Ipsen at EASL Congress 2026
What we heard at the EASL Congress 2026!
We are back from the European Association for the Study of the Liver (EASL) Congress 2026, Europe’s largest event dedicated to liver health where doctors, scientists, allied health professionals, patients, and industry partners come together to share knowledge, highlight scientific breakthroughs, and build meaningful connections.
Our presence at EASL Congress 2026 reflected our continued commitment to driving progress in rare liver diseases. Through six scientific presentations – including three late‑breaking posters – expert‑led symposia and Meet the Expert sessions, we contributed to the advancement of science and supporting meaningful conversations about improvements in patient care.
At Ipsen, rare liver diseases are a core focus of our portfolio. We apply our scientific expertise across five rare cholestatic liver diseases: primary biliary cholangitis (PBC), progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), biliary atresia (BA), and primary sclerosing cholangitis (PSC).
Through our clinical development programs, we aim to advance scientific understanding of rare liver diseases and their impact on the people who live with them. As these conditions can present in unpredictable ways, personalized management is essential, not only to control disease progression but also to address the symptoms that matter most to people living with a rare liver disease.
Outcomes improve when people living with a rare liver disease understand their condition, and when they are active partners in ongoing goal setting and reviews with their healthcare teams.
A collaborative, holistic approach means bringing together patients, carers, and multidisciplinary professionals, who listen to each other and understand the impact of diseases, including life impacting symptoms such as fatigue and pruritus. This will ensure that management plans reflect clinical priorities while fully accounting for the realities of living with a rare liver disease.
Ipsen’s Hugo Gomes da Silva has been sharing exclusive behind-the-scenes insights from EASL Congress 2026
Reporting live from EASL Congress 2026, Hugo Gomes da Silva, SVP Global Medical Affairs (Rare Disease) captured key moments and standout highlights shaping this year’s meeting. New episodes will be uploaded daily throughout the congress:
Learning more about PBC and Fatigue
An exciting development at this year’s EASL Congress 2026, is the increased recognition of the need to assess and actively manage fatigue in PBC due to its significant burden.
Fatigue in PBC is far more than just being tired; it is a distinct, debilitating clinical symptom that fundamentally alters a person’s quality of life. It is a profound, persistent lack of energy that forces difficult daily choices, impacting everything from physical movement and cognitive function to emotional and social well-being. By affecting even the simplest tasks and personal interactions, PBC-related fatigue necessitates a dedicated approach to care.
Discover more about the reality of living with PBC fatigue here.
Bringing the patient voice to Barcelona
Ipsen is shaping the dialogue around PBC, advocating for proactive management that addresses both disease progression and the debilitating symptoms impacting patients’ daily lives.
During EASL Congress 2026, the streets of Barcelona featured the powerful testimonials of Gill, Jo, and Wendy from the This is My PBC campaign. By bringing their lived experiences directly to the medical community, these stories served as a vital reminder to attending HCPs that effective care requires a dual focus on both clinical disease control and symptom management.
Seeing our data spark discussion and recognizing its potential to influence real‑world care reinforced an important truth: our science is driven by purpose
How useful was this post?
Click on a star to rate it!
